127485-56-7

Upstream product

• 3978-80-1 Boc-Tyr-OH 
• 2592-95-2 benzotriazol-1-ol 

Downstream Products

• 84979-58-8 Boc-Tyr-NHNH-Troc 
• 98441-63-5 C₄₃H₆₈N₁₀O₁₃S 
• 84979-54-4 Boc-Tyr-Leu-NHNH-Troc 
• 179631-89-1 tert-butyl (S)-(1-(benzylamino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamate 
• 40829-21-8 (S)-2-amino-N-benzyl-3-(4-hydroxyphenyl)propanamide 
• 1370356-29-8 C₂₄H₃₁N₃O₅ 
• 1370356-27-6 octanedioic acid [1-benzylcarbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide 
• 1263819-90-4 N-((N-chlorambucilylamino)hexanoyl)-p-hydroxyphenyl-L-p-tyrosinamide 
• 1263819-88-0 N-((N-Boc-amino)hexanoyl)-p-hydroxyphenyl-L-p-tyrosinamide 
• 1263819-85-7 N-chlorambucilyl-p-hydroxyphenyl-L-p-tyrosinamide 
• 179631-33-5 N-Boc-p-hydroxyphenyl-L-p-tyrosinamide 
• 64963-27-5 N-tert-butyloxycarbonyl-L-tyrosyl-glycyl-glycyl-L-phenylalanyl-L-leucine 
• 84979-55-5 Boc-Leu-Tyr-Leu-NHNH-Troc 
• 84993-67-9 C₅₃H₆₅N₁₃O₁₄ 

Relevant academic research and scientific papers

18F-Trifluoromethylation of Unmodified Peptides with 5-18F-(Trifluoromethyl)dibenzothiophenium Trifluoromethanesulfonate

The 18F-labeling of 5-(trifluoromethyl)-dibenzothiophenium trifluoromethanesulfonate, commonly referred to as the Umemoto reagent, has been accomplished applying a halogen exchange 18F-fluorination with 18F-fluoride, follo

ANTICANCER AGENTS BASED ON AMINO ACID DERIVATIVES

The present invention provides compounds of formula (I): in which T is L or -A-NH-C(O)-L-; L is -(CH2)n- or -(CH2)p-Z-; A is -(CH2)m- or an alkyl component of a naturally occurring amino acid; R is -CO2R1, -CH2OH, -C(O)NH(hydroxyphenyl) or C(S)NH(hydroxyphenyl); R1 is H or is C1-C12 alkyl; X is -OH, OSO2R2, -Cl, -Br, or -I; R2 is C1-C12 alkyl or -CF3; Z is phenyl or naphthyl; m is an integer having a value of 1 to 20; n is an integer having a value of 1 to 20; and p is an integer having a value of 1 to 20 or an enantiomer, diastereoisomer, racemic mixture, pharmaceutically acceptable salt, solvate or prodrug thereof. These compounds can be useful as anticancer agents.

Histone deacetylase inhibitors: Synthesis of tetrapeptide analogue saha/tpx

The inhibition of HDAC (histone deacetylase) activity by specific inhibitors induces growth arrest, differentiation and apoptosis of transformed or everal cancer cells. Some of these inhibitors are in clinical trial at phase I orphase II. The discovery an